Drug intelligence / Profile preview

Skyvaricella

Development stage: Phase 4
Lead developer: SK bioscience
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Skyvaricella is a live attenuated vaccine developed by SK bioscience Co., Ltd. for the active immunization and prevention of varicella (chickenpox). It is a preparation of the Oka/SK strain of live, attenuated varicella-zoster virus, propagated in human diploid cells (MRC-5). The vaccine works by inducing an immune response to varicella infection. It obtained marketing approval in Korea in June 2018 and received WHO Pre-qualification (PQ) certification in 2019. SK bioscience is also conducting a global Phase 3 clinical trial to evaluate a 2-dose regimen of Skyvaricella.

Brand names: SKYVaricella Inj.
Other names: varicella vaccine (live)SK bioscience varicella vaccine

Beyond the preview

Go deeper on Skyvaricella.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skyvaricella.

Explore the full profile